<DOC>
	<DOCNO>NCT01320345</DOCNO>
	<brief_summary>The purpose study evaluate potential benefit Fenofibrate 300 adult Type 1 diabetes mellitus high risk eye damage .</brief_summary>
	<brief_title>A Trial Adults With Type 1 Diabetes Mellitus Evaluating Effects Fenofibrate Versus Placebo Macular Thickness Volume</brief_title>
	<detailed_description>Diabetes common cause adult onset blindness . Vision loss , irreversible , feared complication diabetes . A blood fat lower drug call fenofibrate , available Australia , show reduce eye damage people Type 2 diabetes 35-40 % , prevent eye damage Type 1 diabetic animal model . This study evaluate potential benefit oral Fenofibrate 145mg daily 12 month 300 adult Type 1 diabetes mellitus high risk eye damage .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Subjects type 1 diabetes mellitus Over 18 year age Established macular thicken optical coherence tomography ( OCT ) great equal 300 micrometres least one macular zone No definite indication receiving , contraindication receive fenofibrate addition exist therapy Subjects type 1 diabetes mellitus contraindication definite need intraocular treatment photocoagulation therapy within next 3 month Allergy fibrate drug History pancreatitis pulmonary embolism DVT Use investigational agent last 8 week Unstable condition include recent MI , heart failure , prior organ transplant , severe renal liver dysfunction , history myositis untreated hypothyroidism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>Retinopathy</keyword>
	<keyword>Diabetic Nephropathy</keyword>
	<keyword>Fenofibrate</keyword>
</DOC>